• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·China·Healthcare·600201.SS
Share

Jinyu Bio-technology Co., Ltd. Stocks

CN¥ 13.12Last Updated 27.10.2026

Issuer Rating

4/7
Performance

Modest

Risk

Low

Recommendation

Hold

Market Cap

CN¥ 2.18B

CN¥ 13.12
Key Takeaways

Risk factor

Strong trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly overvalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Based in Hohhot, China, Jinyu Bio-technology Co., Ltd. is a Chinese firm specializing in the development, production, and commercialization of biological products for animal health. Established in 1992, the company provides crucial vaccines designed to combat diseases such as foot-and-mouth disease, highly pathogenic avian influenza, brucellosis, rabies, and swine fever. These vital immunizations are supplied for a broad spectrum of animals, including pigs, poultry, ruminants, and companion pets. The entity formally adopted its current name, Jinyu Bio-technology Co., Ltd., in December 2015, having previously operated as Inner Mongolia Jinyu Group Co., Ltd.

Company Valuation

Greatly overvalued
1/7

From both historical and forecast perspectives, the stock is considerably overpriced compared to similar stocks. In particular, the stock is overpriced on P/E, 'expensive

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Slightly negative
3/7

The average target price of 600201.SS is 11.5 and suggests 11.4% downside potential. Usually, this means a SELL recommendation among investment firms, or a recommendation

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

28.10.2026 03:18

"The conditions for a rebound are ripe": Stocks rise for a second day ahead of big tech earnings reports

28.10.2026 03:13

Oracle is expanding its partnership with OpenAI and integrating Google chips into its infrastructure

28.10.2026 00:20

Memory stocks cool off in 2H26 amid AI spending doubts

27.10.2026 22:38

GM will move its listing to the Nasdaq. What does this mean for its stock?

27.10.2026 21:09

Boeing shares plunge as 737 Max ramp-up delays overshadow top-line growth in 3Q

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026